HHS to Update Testosterone Therapy Warning Labels

• The Division of Well being and Human Companies (HHS) has proposed key adjustments to the labeling of testosterone alternative remedy (TRT) merchandise.
• The proposed adjustments might increase entry to TRT for males with idiopathic and age-related hypogonadism.
• In accordance with HHS Secretary Robert F. Kennedy, Jr., the adjustments replicate probably the most present scientific proof on the dangers and advantages of TRT.

The Division of Well being and Human Companies (HHS) introduced plans on June 18 to replace label info for testosterone replacement therapy (TRT) merchandise, marking a big shift in coverage.

“Throughout Males’s Well being Month, we’re placing science again on the heart of males’s healthcare,” HHS Secretary Robert F. Kennedy Jr. mentioned within the announcement. “By updating testosterone remedy labels to replicate present proof, we’re giving sufferers and physicians clearer info, supporting knowledgeable medical selections, and enhancing look after tens of millions of American males.”

The announcement follows a December 2025 meeting of FDA experts, throughout which the panel signaled broad assist for increasing entry to TRT.

In April, the FDA made an announcement encouraging producers of authorised TRT merchandise to discover a possible new indication for low libido in males with idiopathic hypogonadism, or low testosterone with no recognized underlying trigger.

Presently, FDA-approved TRT merchandise could solely be prescribed for types of hypogonadism with particular genetic or structural causes.

Federal officers say the adjustments replicate a rising physique of proof supporting the security and effectiveness of testosterone remedy when appropriately prescribed and monitored. For sufferers, the proposed updates might increase entry to remedy whereas additionally clarifying dangers based mostly on probably the most up-to-date proof.

The announcement was supported by males’s well being specialists interviewed by Healthline, who agreed that TRT-associated cardiovascular, prostate most cancers, and BPH danger have been overstated.

The proposed labeling revisions deal with three main areas: age-related hypogonadism, prostate most cancers danger, and BPH.

The FDA is requesting the elimination of a limitation stating that the security and effectiveness of testosterone alternative remedy haven’t been established in males with age-related hypogonadism. The situation refers back to the gradual decline in testosterone that may happen with getting older, somewhat than on account of an identifiable medical situation.

That limitation was added in 2015, when issues arose about potential cardiovascular dangers related to testosterone remedy, and proof supporting its use was thought-about restricted.

Since then, further knowledge have emerged, together with the TRAVERSE trial, a big research involving greater than 5,200 males. In accordance with HHS, the trial discovered no significant enhance within the danger of main antagonistic cardiovascular occasions, together with heart attack and stroke, amongst males receiving testosterone alternative remedy.

Based mostly on its overview of the TRAVERSE findings and different out there proof, the FDA concluded that the limitation is not warranted.

Franck Mauvais-Jarvis, MD, PhD, a professor of medication at Tulane College and director of the VA hormone remedy clinic at New Orleans Medical Middle, known as the choice “a vital victory.”

Different specialists mentioned the findings reinforce what many males’s well being specialists have recognized for years.

“Even earlier than this trial had been carried out, it was well-known within the males’s well being neighborhood that testosterone alternative inside physiologic ranges is secure and mustn’t trigger antagonistic cardiovascular occasions. This research reinforces this widespread data,” mentioned S. Adam Ramin, MD, board licensed urologist, urologic oncologist, and medical director of Urology Most cancers Specialists in Los Angeles, California.

Nevertheless, he emphasised that security relies upon closely on sustaining testosterone ranges throughout the regular physiologic vary.

In accordance with Ramin, clinicians ought to typically goal testosterone ranges between roughly 350 and 750 ng/dL. Tremendous physiologic ranges considerably above that vary could enhance purple blood cell manufacturing and doubtlessly elevate the risk of blood clots, coronary heart assault, or stroke.

Ramin added that testosterone alternative has additionally been proven to be efficient: constantly elevating testosterone ranges and enhancing signs related to low testosterone. He famous that remedy could assist forestall muscle loss and osteoporosis in appropriately chosen people.

“I’m in settlement with the FDA eradicating this warning label. Nevertheless, I might additionally recommend that healthcare suppliers attempt to take care of their sufferers’ testosterone ranges throughout the physiological vary,” he mentioned.

The FDA can also be proposing substantial revisions to longstanding prostate most cancers warnings.

Present labeling typically states that testosterone remedy shouldn’t be utilized in males with recognized or suspected prostate most cancers and warns that remedy could enhance the danger of creating prostate most cancers.

Below the proposed adjustments, testosterone remedy could be contraindicated solely in males with metastatic prostate most cancers.

Mauvais-Jarvis mentioned the declare that TRT causes prostate most cancers is “a delusion.”

“There is no such thing as a proof that TRT promotes prostate most cancers,” he mentioned.

In accordance with HHS, out there medical trial and epidemiologic proof haven’t typically proven an elevated danger of prostate most cancers amongst males receiving testosterone alternative remedy.

Nevertheless, they acknowledge that some uncertainty exists as a result of prostate most cancers can take years to develop.

Ramin additionally concurred that present proof doesn’t assist the concept that testosterone remedy causes prostate most cancers.

“It’s false to state that testosterone alternative could trigger prostate most cancers,” he mentioned. “There is no such thing as a scientific proof for this sort of an announcement.”

He famous that testosterone could speed up progress of an already present prostate most cancers, however that differs from inflicting most cancers to develop within the first place.

He agreed with the FDA’s emphasis on screening and monitoring, describing prostate cancer risk evaluation as an necessary element of testosterone remedy. He additionally agreed that males with metastatic prostate most cancers mustn’t obtain TRT.

In accordance with Ramin, applicable screening will help establish sufferers who could safely endure remedy. He famous that some males with a historical past of handled prostate most cancers who’ve remained disease-free for greater than two years, in addition to sure males with low-grade, dormant prostate cancers, could also be thought-about for TRT in chosen circumstances.

On the similar time, he cautioned towards overinterpreting the proposed labeling revisions.

“Whereas I agree with the proposed adjustments, you will need to observe that the proposed change doesn’t particularly say TRT is secure in males with localized or non-metastatic prostate most cancers. It merely says that it isn’t secure in males with metastatic prostate most cancers,” he mentioned.

The FDA is requesting updates to warnings associated to benign prostatic hyperplasia, or enlarged prostate.

Present labeling warns that testosterone remedy could worsen signs of the situation.

Nevertheless, in accordance with the HHS announcement, out there medical trial knowledge don’t exhibit worsening signs in males with delicate to reasonable BPH, though some proof exists for males with extra extreme signs.

Below the proposed revisions, labeling would proceed to advocate monitoring sufferers who’ve extreme symptomatic illness.

Ramin mentioned he helps the change.

“Testosterone alternative in a person with delicate to reasonable BPH must be secure so long as they’re adopted with correct supervision,” he mentioned.

In accordance with Ramin, monitoring ought to embody periodic evaluation of urinary signs, routine measurement of the Worldwide Prostate Symptom Rating (IPSS), and periodic prostate ultrasounds to guage whether or not the prostate stays secure or continues to develop throughout remedy.